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Summary. Objective: Health benefits of conjugated fatty acids, particularly conjugated linolenic acid (CLNA), 
have recently provide substantial insights in a variety of obesity-related tumorigenesis including breast neoplasia. 
This study aims to investigate the effects of CLNA-contained oil (CLNAO) supplementation on central obesity 
indices and blood pressure in women with benign breast disease (BBD). Methods: Forty six pre-menopausal 
women with BBD were randomly allocated to intervention group (n=23) or placebo (n=23). Patients in the 
intervention group received 1000 mg/day CLNAO capsule and the placebo group received 1000 mg/day inert 
oil-contained capsule during 13 weeks. Measures of blood pressure and some anthropometric variables were 
performed at the baseline and end of study. Result: Systolic (P<0.01) and diastolic (P<0.05) blood pressures 
decreased within CLNAO group on subjects whom were overweight. Normal weight participants who received 
placebo showed significant increases in total body fat (P<0.05), waist circumference (P<0.05), and waist circum-
ference to height ratio (P<0.05), meantime CLNAO group showed no changes on both variables. Intervention 
with CLNAO caused no significant increases on skinfolds of abdomen and suprailiac, whereas these measures 
were remarkably increased in placebo (P<0.001 and P<0.05, respectively). Conclusion: Findings from this study 
show that CLNAO can attenuate development of central fat acquisition in the BBD patients who weighted 
normally. Administration of CLNAO decline systolic and diastolic blood pressures of overweight subjects. 
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Introduction
Great numbers of breast disorders have a network 
to benign lesions of breast (1). Premenopausal women 
experience benign breast disease (BBD) by a far more 
frequent rate than breast carcinoma (BC) (2). Fibrocys-
tic change and fibroadenoma are the  most common be-
nign lesions that occur in breast (3). Women with lobu-
lar/ductal proliferative tumors indicates larger risk for 
later developing of breast cancer (BC) (4, 5). Indicators 
related to excess deposition of fat in abdomen, including 
waist circumference (WC) and WC to hip ratio (WHR) 
grant strong risks for breast neoplasia (6-8). Increase in 
circulating insulin and insulin like growth factors, and 
inflammatory dysfunction of adipocytes are considered 
as risk factors for developing BC in either obese pre/
postmenopausal women (9, 10). It is reported that WC 
to height ratio (WHtR) is a useful predictor employed 
along with WHR to assess the risk of metabolic disor-
ders (11). Epidemiological studies revealed an expressive 
relation among blood pressure, central obesity, and breast 
neoplasia (12-14). Obesity represses circulating amount 
of adiponectin, as a predictor condition  for later hy-
pertension, even among normotensive people (15, 16). 
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Moreover, it is reported that prevalence of hypertension 
was significantly higher in BC-affected patients versus 
BBD subjects, despite of same distribution of body fat 
(12). In fact, hypertension can also be a tumorigenic fac-
tor associated with disturbance of circulating androgen 
to estrogen ratio (13). 
There are growing research findings concerning 
in protective effects of conjugated fatty acids (CFA) 
against a variety of disorders ranging from obesity to 
breast tumorigenesis (17-19). CFA referred to two iso-
meric types of linoleic and linolenic acid (CLA and 
CLNA), which may contain cis (c) and/or trans (t) 
bonds (20, 21). Evidences from interventional clinical 
literatures suggest an anti-adipogenic role for CLA/
CLNA in healthy people who were overweight and 
obese (22-24). These findings even have been support-
ed by experimental animal studies concerned CLNA 
in rodents exposed to a high-fat diet (25, 26). Cur-
rently, mitigating efficacy of CLA in the obesity-relat-
ed hypertension has been shown in the interventional 
human studies and animal experiments (27, 28). How-
ever, a literature worked on healthy non-obese subjects 
described no significant change in blood pressure after 
CLA consumption (29).  
Considering the BC-specific turmoil in BBD pa-
tients, examining control strategies for this disease can 
be very important in health care of patients. Therefore, in 
this study, we tend to check the interaction between cen-
trally distributed body fat and variations in blood pressure 
in BBD patients who received CLNAO supplement.
Materials and Methods
Subjects and design
The present study is a randomized controlled clin-
ical trial conducted as a parallel design, double blind 
study. The study was started in June 2014 and contin-
ued till May 2015, lasting 11 months. Inclusion crite-
ria included BMI <35 kg/m², lack of breastfeeding and 
pregnancy during the intervention and over the past 
year, not taking supplements that confuse outcomes, 
such as omega-3, evening primrose oil, and weight loss 
supplements, and not receiving derivatives of estrogen 
and progesterone hormones (over the past 6 months) or 
drugs such as glucocorticoids, anti-diabetic, and blood 
pressure controlling drugs. Exclusion criteria were his-
tory of any malignancy or receiving conventional treat-
ment for cancer, thyroid disorders, liver dysfunction, 
gastro-intestinal diseases, and hormonal disorders. 
Additionally, people with moderate to severe physical 
activity, smokers and alcoholics were excluded. Objec-
tives and methodology of the study were described to 
the patients. A questionnaire about medical history 
and demographic information was completed in par-
ticipants by a skilled interviewer at the beginning of 
the study. Study subjects were also asked about physi-
cal activity level using a metabolic equivalent of task 
(MET)-hour-based physical activity questionnaire. 
Women with confirmed fibrocystic disease (n=42) fi-
broadenoma (n=1) or both types of lesions (n=3) on 
pathologic or sonographic examination, aged 25-47 
years, from NoureNejat hospital outpatient clinic at 
Tabriz (North-West Azerbaijan province of Iran) par-
ticipated in the study (Figure 1). Questionnaires about 
physical activity level and used drugs or supplements 
were repeated to ask in the weeks 4, 8, and the end of 
study. At the enrolment, all participants were trained 
to complete their daily food record for three days (two 
typical working days and one weekend day) by using 
sample of utensil units and list of foods with serving 
size. Dietary records were returned by patients in base-
line, weeks 4, 8, and the end of trial. Recorded foods 
were converted into grams using household scales by 
an expert nutritionist. Finally, the average intake of 
each certain nutrient was obtained by means of Nu-
tritionist IV software (version 3.5.2; 1994, N-Squared 
Computing, San Bruno, CA).
This study received approval of Ethics Committee 
of Tabriz University of Medical Sciences (Ethics no: 
936). The clinical trial was conducted after with reg-
istration at Iranian Registry of Clinical Trials (IRCT) 
(IRCT no: IRCT2014050411335N3). A written in-
formed consent form was provided by each partici-
pant prior to the recruitment. Patients were assured 
that their personal information will be confidential. 
Intervention
Each of study subjects received a unique code. 
Opaque packages containing capsules were encoded 
A and B by factory to observe triple-blind state of 
the study. Two groups, intervention and placebo, were 
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formed using a random list obtained from random al-
location software. The third person who was unaware 
of the grouping was responsible for distributing sup-
plements. In this study, 1000 mg/day pomegranate 
seed oil (PSO), which contained 75% c9, t11, c13-
CLNA, in the form of a soft gel capsule was given to 
the intervention group. Subjects were asked to keep 
their usual diet and life style during the study. The pla-
cebo group received soft gel capsules containing 1000 
mg of inert oil (containing 350 mg sunflower oil, 350 
mg palm olein and 300 mg corn oil) based on common 
oils used in Iranian families (30). The oil content of 
placebo and supplements were combined with10 IU 
α-tocopherol (Nature Made, USA) and changed into 
soft gel capsules in Barij Essence pharmaceutical com-
pany, Kashan, Iran. Palm olein, sun flower and corn 
oil respectively were provided by NahanGol, Oila, and 
Famila companies (Tehran, Iran). Intervention and 
placebo pearls were similar in terms of shape, size and 
color. The run-in period for all patients was considered 
to be 2 weeks, in which they were not supposed to use 
compounds such as flaxseed, soy bean/protein, green 
tea, nuts or broccoli. The mean durations of interven-
tion in the placebo and intervention groups were 90.56 
and 93 days (average 13 weeks), respectively. Capsules 
were offered in an opaque container for 4 weeks. The 
patients were asked to complete the checklist of cap-
sules taken during this period and return the rest that 
were not taken at the end of 4 weeks. If the patients 
had taken less than 85% of capsules intended for each 
individual, they were excluded. The patients were fol-
lowed up using telephone calls weekly to control ab-
normal reactions due to the use of supplements. 
Supplement safety and content
The fatty acid composition of cold-press extracted 
seed oil was analyzed by gas chromatography. Punicic 
acid (PA), c9, t11, c13-CLNA, and its isomers formed 
75% of oil compounds. In addition, a fat oxidation test 
showed 0.3 mg of potassium hydroxide per gram of oil 
Figure 1. Consort Flow Chart of Treatment
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(<0.7 mg KOH: g oil as normal value) and the Kreis 
test (to check for epihydrin aldehyde/malonaldehyde) 
for oil compound was negative.
Anthropometric measurements
Actual body weight, height, WC and hip circum-
ference (HC) of the patients were measured at the 
baseline and 13 weeks following the intervention. The 
patients’ height without shoes was measured using a 
stadiometer (Seca, Germany) with an accuracy of 0.5 
cm. The patients’ weight with light clothing and with-
out shoes was measured using a digital scale (Seca, Ger-
many) with an accuracy of 0.1 kg. The body mass index 
(BMI) was calculated by dividing patients’ weight (kg) 
by their height (m2). WC was evaluated with an ac-
curacy of 0.1 cm in the narrowest region between the 
last rib and the iliac crest bone when the person was at 
the end of her natural expiration. HC was measured 
using a tape measure with an accuracy of 0.1 cm and 
WHR and WHtR were obtained through mathemati-
cal calculation. Total body fat percent (TBF) measure-
ment was done using the body fat analyzer (EZ-Care-
BF108E, Taiwan) after measuring twice at intervals of 
5 minutes. Skinfolds were also measured on the right 
side of body using a skinfold caliper over the abdomen 
and the suprailiac, 3 times at intervals of 5 minutes. 
Average measured values were used for analysis. 
Measuring blood pressure
Systolic and diastolic blood pressures were mea-
sured after 10 minutes of relaxation, with subjects 
in sitting position at a comfortable room, using a 
digital sphygmomanometer (Beurer-BM60, Ger-
many). Blood pressure was measured on the right 
arm placing at the right atrium level, three times at 
intervals of 5 minutes and the average of the sec-
ond and third measures was recorded for analysis. 
Statistical methods
Data were analyzed by means of SPSS software 
(version 13). Distribution of data was checked by 
histogram and the Kolmogorov-Smirnov test. Nor-
mal quantitative variables were reported by mean and 
standard deviation (S.D.) and qualitative variables 
by frequency and percentage. Independent t-test and 
Mann-Whitney U test were used to compare the 
means between the two groups. Paired t-test and re-
peated measure of analysis of variance (RM-ANOVA) 
was used to compare mean values of the quantitative 
variable in each group. Correlation coefficient between 
variables was performed by bivariate Pearsons’ correla-
tion test. Chi-square analysis was done for ordinal and 
nominal scale data. Analysis of covariate (ANCOVA) 
was employed to provide adjusted outputs. Subgroup 
analysis was carried out to detect subgroup of par-
ticipants that displayed differential treatment effect. 
P<0.05 was considered statistically significant level.
Results
Forty six patients (92%) completed this 13-week 
study, with 23 patients in each group (Figure 1). Weekly 
monitoring of patients reported no side effects of the 
supplements. The baseline demographic and clinical 
characteristics of study population are summarized in 
Table 1. The mean age of the placebo and interven-
tion groups (years ± S.D.) were 32.6±6.2 and 34.2±6.9. 
Comparing the average dietary intake (including daily 
amounts of macro- or micro-nutrients and total calorie 
intake) and physical activity levels at baseline, weeks 4, 
8, and after 13 weeks showed no statistically significant 
difference (data not shown). The mean values of blood 
pressure and anthropometric variables are represented 
in table 2. There were no significant differences in an-
thropometric indices (Weight, BMI, TBF, WC, HC, 
WHR, WHtR, abdominal and suprailiac skinfolds) and 
blood pressure (systolic and diastolic blood pressures) 
between the two groups at the beginning and end of 
study. However, both PSO and control groups showed 
a significant increase in abdominal skinfold (P<0.01 
in both groups) during the study. The mean values of 
systolic and diastolic blood pressures significantly de-
creased within both groups (P<0.05 in both groups) as 
compared with baseline values. After covariate adjust-
ment for potential possible confounder (actual body 
weight and baseline values), no statistical significant 
changes in absolute treatment effects were detected. 
Table 3 shows a subgroup analysis for the variable 
“body weight”, which participants were categorized 
into 2 groups based on their baseline median values. 
Comparison of dietary intake between the two sub-
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group showed participants in the lower half of body 
weight distribution consumed a significantly higher 
calorie per kg of body weight (P<0.05) than subjects 
in upper category at the baseline and after 13 weeks. 
In patients who were under the subgroup of weight 
less than the median (body weight≤64.45 kg), their 
weight, BMI and TBF increased 2.0%, 2.0% and 2.7% 
in the placebo group, respectively (P<0.05),  whereas, 
PSO caused no significant increases on these measures 
(Figure 2). Placebo group showed significant increases 
in WC and WHtR (P<0.05 in both variables) as com-
pared with baseline values, while PSO group experi-
enced no changes on both variables during the study 
(Figure 2). Accordingly, the placebo group had larger 
increase in abdominal (11.6%, P<0.01) and supraili-
ac (7.6%, P<0.05) skinfolds compared to PSO group 
(mean percentage changes of 7.1% and 6.7%, respec-
tively), from baseline to week 13 (Figure 2). 
In the subgroup of patients with a body weight 
higher than the median (body weight> 64.45 kg), the 
average systolic (mean percentage change of -5.0%, 
p<0.05) and diastolic (mean percentage change of 
-6.0%, P<0.01) blood pressures significantly decreased 
within the PSO group at week 13 compared with 
baseline values (Figure 3). However, patients in the 
placebo group showed no significant change in the 
systolic (mean percentage change of -2.1%) and dia-
stolic (mean percentage change of -3.3%) blood pres-
sures during the study.
Table 1. Demographic and clinical characteristics of the intervention and placebo groups at the baseline of study.
Characteristics Placebo (n=23) Intervention (n=23) P-value
Age (years)a   
  At diagnosis (mean±S.D.) 31.91±6.42 32.86±6.89 0.629b
  At first delivery (mean±S.D.) 22.62±3.55 23.05±3.56 0.729b
  At first menses (mean±S.D.) 13.09±1.30 13.30±1.25 0.580b
  At enrolment (mean±S.D.) 32.56±6.25 34.17±6.87 0.411b
Lactation (N (%))c
  ≤1 15 (65.20) 15 (65.20) 1.000d
  ≥2 8 (34.80) 8 (34.80) 
Parity (N (%))c
  ≤1 15 (65.20) 15 (65.20) 1.000d
  ≥2 8 (34.80) 8 (34.80) 
Marital status (N (%))c
  No  5 (21.70)  4 (17.40) 0.710d
  Positive  18 (87.30) 19 (72.60) 
Higher education (N (%))c
  No  14 (60.90)  14 (60.90)  0.1000d
  Positive  9 (39.10) 9 (39.10) 
Histopathological characteristics (N (%))c
  Fibrocystic  20 (87.00)  22 (95.70) 0.490d
  Fibroadenoma  1 (4.30) 0 (0.00) 
  Fibrocystic and fibro adenoma  2 (8.70) 1 (4.30) 
Family history of BC (N (%))c
  No  21 (91.30)  18 (78.30) 0.218d
  Positive  2 (8.70) 5 (21.70) 
Family history of BBD (N (%))c
  No  19 (82.60) 19 (82.60) 1.000d
  Positive  4 (17.40) 4 (17.40)
BC, breast cancer; BBD, benign breast disorders. aData were expressed in geometric mean±S.D. bIndependent sample t-test was performed. c 
Data were expressed in the form of number of participants (relative frequency). d Chi-square test was performed.
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Discussion
This study aimed to look at the impact of CLNAO 
administration on indicators related to central obesity 
and blood pressure in patients with BBD. To our best 
knowledge, no human study presently is conducted to 
examine health benefits of CLNAO in BBD patients 
in regard with controlling central fatness and blood 
Table 2. Anthropometric and blood pressure variables at baseline and 13 weeks after the intervention in women with BBD who 
received PSO supplementation (PSO group( versus placebo capsules consumers.
 Baseline (n=46) 13-week  P (absolute 
  follow-up (n=46) treatment effect)b
Variable n Mean S.D. Pa n Mean S.D. Pa 
Weight (kg)         
Control 23 65.91 15.35 0.853 23 65.94 15.34 0.745 0.452
PSO 23 66.71 13.94  23 67.38 14.45  
BMI (kg/m2)         
Control 23 25.75 5.37 0.989 23 25.75 5.31 0.854 0.427
PSO 23 25.77 4.68  23 26.03 5.07  
Waist girth (cm)         
Control 23 87.18 12.15 0.857 23 87.40 12.26 0.848 0.944
PSO 23 87.80 10.96  23 88.07 11.34  
HC (cm)         
Control 23 105 10 0.896 23 105 10 0.993 0.529
PSO 23 105 8  23 105 9  
WHR         
Control 23 0.82 0.04 0.811 23 0.82 0.04 0.664 0.514
PSO 23 0.82 0.05  23 0.83 0.05  
WHtR         
Control 23 0.54 0.07 0.965 23 0.54 0.07 0.955 0.606
PSO 23 0.54 0.06  23 0.54 0.07  
S.SF (mm)         
Control 23 34.86 12.34 0.543 23 35.67 12.37 0.637 0.859
PSO  23 32.89 9.33  23 34.06 10.53  
A.SF (mm)         
Control 23 39.82 13.60 0.475 23 41.97* 12.37 0.672 0.478
PSO 23 37.34 9.34  23 40.50* 11.10  
TBF (%)         
Control 23 33.76 7.41 0.934 23 33.75 7.16 0.791 0.448
PSO 23 33.93 6.71  23 34.32 7.16  
S.BP (mmHg)         
Control 23 113 8 0.343 23 109** 7 0.652 0.814
PSO 23 111 9  23 108** 9  
D.BP (mmHg)         
Control 23 77.13 8.41 0.299 23 73.30** 5.93 0.235 0.509
PSO 23 74.31 9.51  23 70.75** 8.17  
BMI, body mass index; HC, hip circumference; WHR, waist circumference to hip ratio; WHtR, waist circumference to height ratio; S.SF, suprailic 
skinfold; A.SF, abdominal skinfold; TBF, total body fat; S.BP, systolic blood pressure; D.BP, diastolic blood pressure. All data were expressed in geo-
metric mean±S.D. Mean values were significantly different within the groups using paired t test: *P<0.01, **P<0.05 . a Independent sample t-test 
was performed between the groups. b Analysis of covariance with 13-week follow-up values adjusted by baseline values and weight.
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pressure. The findings of this study suggest that among 
participant with lower body weight, subjects who re-
ceived PSO remarkably experienced lower elevation in 
abdominal obesity indexes including WC, WHtR and 
skinfolds of abdomen and suprailiac compared with 
subjects in the placebo group. It is reported that weight 
gain and fat accumulation around the waist and hip in 
BBD women before menopause is associated with an 
Figure 2. Mean percentage change of anthropometric variables before and after treatment in the placebo ( ) and intervention ( ) 
groups for participants with a baseline body weight of ≤64.45 kg. BMI, body mass index; WC, waist circumference; HC, hip circum-
ference; WHR, waist to hip ratio; WHtR, waist circumference to height ratio; TBF, total body fat; S.SF, suprailiac skinfold; A.SF, 
abdominal skinfold. Independent sample t-test was performed between the groups.
Figure 3. Mean percentage change of blood pressure variables before and after treatment in the placebo ( ) and intervention ( ) 
groups participants with a baseline body weight of ≤64.45 kg and >64.45 kg. S.BP, systolic blood pressure; D.BP, diastolic blood pressure. 
Independent sample t-test was performed between the groups.
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increased risk of postmenopausal BC (31). 
The major fatty acid of PSO is c9, t11, c13-CLNA 
(PA), by which involves in many key health benefits 
attributed to PSO (26). Studies carried out in animal 
models (25, 26, 32) reported rodents receiving PSO or 
PA contained oil in their diet (1% of total calorie intake) 
along with a high-fat diet, showed a significant attenu-
ation in diet-induced acquisition of body fat and weight 
gain occurrences. While, pomegranate juice seems not to 
be effective in reducing the acquisition of adiposity in-
duced by high calorie/fat diet (33). Interventional clini-
cal trials strengthened that CLA treatment in healthy- 
obese and overweight subjects resulted in a significantly 
lower abdominal adiposity compared with controls (22, 
23). An experimental study on human also suggested 
that receiving PA-contained oil was relevant to reduced 
level of WC and other anthropometric variables (weight 
and TBF) in premenopausal women with a BMI ≥25 
kg/m2 (24). Administration of CFA may be protective 
against body fat gain only in obese/over-weight subjects 
(22-24). Further evidence is provided by a trial in people 
with normal BMI, which reported no beneficial effect 
of CFA on anthropometric indices (34). Accordingly, 
finding of present study, suggesting the fat-loss effect of 
PSO only in subjects with normal BMI, was not in line 
with the findings of previous studies. However, in ani-
mal model experiments, an effective fat-loss events due 
to CLNA/PSO was reported in rodents that received an 
adipogenic regiment (25, 26, 32). Similarly, in the pres-
ent study, variable of “total calorie intake per kg of body 
weight” was significantly higher in the normal-weight 
participants than overweight ones. Therefore, it is prob-
able that the daily calorie intake can be a more important 
factor than body fat for CFA-mediated fat-loss events, 
however this finding needs to replicate in other studies. 
In the current study, despite the slimming effect of 
PSO which was observed for participants in lower half 
of body weight distribution, systolic and diastolic blood 
pressures significantly decreased among participants 
receiving PSO whom were overweight. Declercq et al. 
studied the effect of CLA isomers on obesity-induced 
hypertension in obese fa/fa Zucker rats and found that 
t10, c12-CLA-isomer attenuated the increase in systolic 
blood pressure caused by obesity, after 8 weeks of feed-
ing (27). The results of a clinical trial have shown that 
with combined administration of isomers mixture of c9, 
t11-CLA and t10, c12-CLA with Ramipril (inhibi-
tor of angiotensin-converting enzyme) in hypertensive 
obese patients, clinical response to the drug significantly 
improved (28), while the use of same isomer mixture in 
healthy men with normal weight exhibited no change in 
the systolic and diastolic blood pressures (29). It seems 
that CLNAO’s reducing effect on obesity-related hyper-
tension is independent of improvements that occurred 
in anthropometric indices, and works by increasing the 
amount of adiponectin that is secreted by adipocytes 
(27). There are very limited studies evaluating CLNA 
and blood pressure in the humans. A trial involving 800 
mg PSO supplementation in hyperlipidemic patients 
showed no significant change in blood pressure dur-
ing 4 weeks (35). Given the dose-dependent function 
of CLNA, heterogeneous result can be because of the 
higher dose that we used. Moreover, CLNA is reported 
to have a time-dependent action (24, 36). The strength 
of the present study may be the longer duration of the 
PSO supplement use. Characteristics of patients en-
rolled in the study may also affect on results. 
Conclusion
Findings from this study showed that adminis-
tration of PSO improved systolic and diastolic blood 
pressures of overweight BBD patients. The increasing 
rate of weight, BMI, TBF and the indices associated 
with central obesity substantially were attenuated in 
normal-weight patients who received PSO, yet they 
consumed more calories per kg of body weight.
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